Clinical Trial

Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Multicenter, open-label, multi-dose study to evaluate the safety and tolerability in patients with nAMD treated with SCT520FF.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-11-01; most recent amendment 2025-08-27.
Status change: Not Yet Recruiting → Recruiting 2025-08-27
Trial Details
NCT Number NCT06672536
Lead Sponsor Sinocelltech Ltd.
Collaborators: Tianjin Medical University Eye Hospital
Conditions nAMD
Enrollment 82 participants
Start Date 2024-11-26
Primary Completion 2026-09-23 (estimated)
Study Completion 2027-01-11 (estimated)
Updated on ClinicalTrials.gov 2025-09-04